Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 66.29% | 61.20% | 4.09% | -17.54% | -33.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.21% | 23.16% | -13.88% | -24.40% | -30.60% |
| Operating Income | -33.21% | -23.16% | 13.88% | 24.40% | 30.60% |
| Income Before Tax | -28.61% | -27.99% | 3.52% | -1.97% | 12.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.61% | -27.99% | 3.52% | -1.97% | 12.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.61% | -27.99% | 3.52% | -1.97% | 12.45% |
| EBIT | -33.21% | -23.16% | 13.88% | 24.40% | 30.60% |
| EBITDA | -33.55% | -23.50% | 13.90% | 24.50% | 30.75% |
| EPS Basic | -16.80% | -20.72% | 7.73% | 1.69% | 15.14% |
| Normalized Basic EPS | -16.89% | -20.81% | 7.74% | 1.74% | 15.24% |
| EPS Diluted | -16.80% | -20.72% | 7.73% | 1.69% | 15.14% |
| Normalized Diluted EPS | -16.89% | -20.81% | 7.74% | 1.74% | 15.24% |
| Average Basic Shares Outstanding | 11.02% | 5.65% | 4.44% | 3.50% | 3.13% |
| Average Diluted Shares Outstanding | 11.02% | 5.65% | 4.44% | 3.50% | 3.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |